Diabetes drug gets FDA approval

Mon, 21 Jan 2008
According to a press release, diabetes drug company Daiichi Sankyo Inc. today announced that the US FDA (Food and Drug Administration) have granted approval for diabetes drug Welchol. The type 2 diabetes drug is hailed as a unique pioneer drug that reduces both forms of cholesterol .

Welchol has been created following statistics that some 40 per cent of type 2 diabetics also suffer from high LDL cholesterol . Welchol plugs a gap in the market, apparently allowing patients to treat both health conditions at the same time.

Welchol has been through several phases of clinical trials, and its efficacy was highlighted during a presentation at the ADA (American Diabetes Association) Scientific Sessions in Chicago last year.

One diabetes expert, Ronald Goldberg MD, was reported as commenting: "Welchol now offers physicians a treatment option that addresses two major cardiovascular risk factors; elevated LDL cholesterol and blood glucose in patients with type 2 diabetes. Cardiovascular risk factors are of great concern because patients with type 2 diabetes have a significantly increased risk of developing cardiovascular disease . Once clinical cardiovascular disease develops, these patients have a poorer prognosis than normoglycemic patients."
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.